WELCOME TO EU-OPENSCREEN
A European Infrastructure of Screening Platforms
EU-OPENSCREEN, the European Infrastructure of Open Screening Platforms for Chemical Biology, integrates high-throughput screening platforms, chemical libraries, chemical resources for hit discovery and optimisation, bio- and cheminformatics support, and a database containing screening results, assay protocols, and chemical information.
These platforms - offering the most advanced technologies - will be used by European researchers from academia and SMEs in order to identify compounds affecting new targets. Open access to an integrated infrastructure for Chemical Biology will thus satisfy the needs for new bioactive compounds in many fields of the Life Sciences (e.g. human and veterinary medicine, systems biology, biotechnology, agriculture and nutrition).
Memorandum of Understanding entered into force
Nine countries (Czech Republic, Finland, France, Germany, Greece, Hungary, Norway, Poland and Romania) and one international organisation (EMBL) are signing EU-OPENSCREEN's Memorandum of Understanding (MoU). The Signatories participate in EU-OPENSCREEN's Transition Committee and will make a dedicated effort to take all necessary steps towards the implementation of the European research infrastructure. Additional partner countries, where negotiations to sign the MoU are on-going, are invited to join the Transition Committee at a later stage.
The EU-funded project BioMedBridges, of which EU-OPENSCREEN is a partner, developed a position paper on the principles of data management and sharing at European Research Infrastructures, which can be downloaded here.
Cambridge Healthtech Institute is proud to announce the Inaugural Chemical Biology for Target Validation conference, established to convene an interdisciplinary collection of leaders in chemical/structural biology, chemical proteomics, medicinal chemistry, synthetic chemistry and chemogenomics to discuss strategies to de-risk novel discovery initiatives. May 22-23, 2014. Westin Boston Waterfront, Boston, MA
EU-OPENSCREEN's 5th Project and 3rd Stakeholder Meeting took place in Oslo, November 19-20, 2013.
See here for the agenda and further information.
Opening of new CZ-OPENSCREEN infrastructure facility in Prague
The Czech Minister for Education Youth and Sports Dr. Dalibor Štys (left), EU-OPENSCREEN coordinator Dr. Ronald Frank (middle), and director of Institute for Molecular Genetics of the Czech Academy of Sciences (IMG) Prof. Dr. Václav Hořejší are cutting the ribbon for the official opening of the new CZ-OPENSCREEN infrastructure facility in Prague on 24th September 2013. (http://www.openscreen.cz/)
To the right: Head of Cell Differentiation Laboratory at IMG and coordinator of CZ-OPENSCREEN. Dr. Petr Bartůněk, head of the new facility. Please click images to enlarge.
When Chemical Biology meets Drug Design
This major international symposium gathered more than 600 scientists from around the world at the Conference Center Nice Acropolis. EU-OPENSCREEN was also presenting at this conference in Nice.
WIRE 2013: Máire Geoghegan-Quinn, commissioner for research, innovation and science, visited the EU-OPENSCREEN poster at the Week of Innovative Regions in Europe (WIRE) Conference in Cork.
EU-OPENSCREEN at IRDiRC 2013: Stakeholders active in the rare disease area from across the globe convened in Dublin at the First International Rare Diseases Research Consortium (IRDiRC) Conference.
A report can be downloaded here.
German Roadmap for large research infrastructures: Based on the evaluation report from the German Council of Science and Humanities (Wissenschaftsrat), the German Federal Ministry of Education and Research (BMBF) included EU-OPENSCREEN in its new Roadmap.
Our new slogan is Chemical Keys for Life's Locks, as announced at the Mid-term Review Meeting in Vienna, in July 2012.
The Preparatory Phase Project receives funding from the
European Union Seventh Framework Programme (FP7/2007-2013)
under grant agreement n° 261861.